PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer
| العنوان: | PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer |
|---|---|
| المؤلفون: | Ni Yu, Masahisa Handa, Laura Q.M. Chow, Terrill K. McClanahan, Jared Lunceford, Joanne E. Tomassini, Christina Moon, Jonathan D. Cheng, Christopher E Gibson, Jennifer H. Yearley, Erin Murphy, Tanguy Y. Seiwert, Jonathan Juco |
| المصدر: | Clinical Cancer Research. 23:3158-3167 |
| بيانات النشر: | American Association for Cancer Research (AACR), 2017. |
| سنة النشر: | 2017 |
| مصطلحات موضوعية: | Adult, Male, 0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Stromal cell, medicine.medical_treatment, Programmed Cell Death 1 Receptor, Pembrolizumab, Antibodies, Monoclonal, Humanized, Disease-Free Survival, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Carcinoma, medicine, Humans, Aged, Aged, 80 and over, Squamous Cell Carcinoma of Head and Neck, business.industry, Cancer, Immunotherapy, Middle Aged, Programmed Cell Death 1 Ligand 2 Protein, medicine.disease, Head and neck squamous-cell carcinoma, Blockade, Gene Expression Regulation, Neoplastic, 030104 developmental biology, Head and Neck Neoplasms, 030220 oncology & carcinogenesis, Immunology, Monoclonal, Carcinoma, Squamous Cell, Female, business |
| الوصف: | Purpose: Tumor-associated PD-L1 expression is predictive of clinical response to PD-1–directed immunotherapy. However, PD-L1–negative patients may also respond to PD-1 checkpoint blockade, suggesting that other PD-1 ligands may be relevant to the clinical activity of these therapies. The prevalence of PD-L2, the other known ligand of PD-1, and its relationship to response to anti-PD-1 therapy were evaluated. Experimental Design: PD-L2 expression was assessed in archival tumor tissue from seven indications using a novel immunohistochemical assay. In addition, relationships between clinical response and PD-L2 status were evaluated in tumor tissues from patients with head and neck squamous cell carcinoma (HNSCC) with recurrent or metastatic disease, treated with pembrolizumab. Results: PD-L2 expression was observed in all tumor types and present in stromal, tumor, and endothelial cells. The prevalence and distribution of PD-L2 correlated significantly with PD-L1 (P = 0.0012– Conclusions: Clinical response to pembrolizumab in patients with HNSCC may be related partly to blockade of PD-1/PD-L2 interactions. Therapy targeting both PD-1 ligands may provide clinical benefit in these patients. Clin Cancer Res; 23(12); 3158–67. ©2017 AACR. |
| تدمد: | 1557-3265 1078-0432 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa02a3b32e295f38058618a53480d54dTest https://doi.org/10.1158/1078-0432.ccr-16-1761Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....fa02a3b32e295f38058618a53480d54d |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15573265 10780432 |
|---|